PACB vs BIO
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 10, 2026
PACB
BIO
Investment Advisor Scores
BIO
AI Analyst Insights
Detailed Metrics Comparison
| Metric | PACB | BIO | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 37.594 | Tie |
| PEG Ratio | -0.17 | 4.0063 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.1% | -0.1% | PACB |
| Earnings Growth | 0.0% | 18.7% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 48.8/100 | 39.6/100 | PACB |
| Profit Margin | -80.3% | 8.6% | BIO |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | SELL | PACB |
Relative Price Performance (Last 90 Days)
Current Technical Phase
PACB
NeutralMixed signals - no dominant trend phase, RSI 61
BIO
MarkupPrice above SMA50, rising 50-day trend (8.1% over 20 days), RSI 81
Fundamentals Snapshot
| Metric | PACB | BIO |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -3.8 | 38.9 |
| Trailing P/E | — | 46.3 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.3% | 0.5% |
| Operating Margin | -1.1% | 0.1% |
| EPS | -0.40 | 8.25 |
| Dividend Yield | — | — |